The company has partnered with MD Anderson Cancer Center to deploy a unique approach to cancer therapeutic monoclonal antibody and target discovery. OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody-derived therapeutics for the treatment of cancer. The company's lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics.